INTRODUCTION: Our goal was to determine whether in vivo administration of the proteasome inhibitor MG132 can prevent muscle atrophy caused by hindlimb unloading (HU). METHODS: Twenty-seven NMRI mice were assigned to a weight-bearing control, a 6-day HU, or a HU+MG132 (1 mg/kg/48 h) treatment group. RESULTS: Gastrocnemius wasting was significantly less in HU+MG132 mice (-6.7 ± 2.0%) compared with HU animals (-12.6 ± 1.1%, P = 0.011). HU was also associated with an increased expression of MuRF-1 (P = 0.006), MAFbx (P = 0.001), and USP28 (P = 0.027) mRNA, whereas Nedd4, E3α, USP19, and UBP45 mRNA did not change significantly. Increases in MuRF-1, MAFbx, and USP28 mRNA were largely repressed after MG132 administration. β5 proteasome activity tended to increase in HU (+16.7 ± 6.1%, P = 0.086). Neither β1 and β2 proteasome activities nor ubiquitin-conjugated proteins were changed by HU. CONCLUSIONS: Our results indicate that in vivo administration of MG132 partially prevents muscle atrophy associated with disuse and highlight an unexpected regulation of MG132 proteasome inhibitor on ubiquitin-ligases.
INTRODUCTION: Our goal was to determine whether in vivo administration of the proteasome inhibitor MG132 can prevent muscle atrophy caused by hindlimb unloading (HU). METHODS: Twenty-seven NMRI mice were assigned to a weight-bearing control, a 6-day HU, or a HU+MG132 (1 mg/kg/48 h) treatment group. RESULTS: Gastrocnemius wasting was significantly less in HU+MG132mice (-6.7 ± 2.0%) compared with HU animals (-12.6 ± 1.1%, P = 0.011). HU was also associated with an increased expression of MuRF-1 (P = 0.006), MAFbx (P = 0.001), and USP28 (P = 0.027) mRNA, whereas Nedd4, E3α, USP19, and UBP45 mRNA did not change significantly. Increases in MuRF-1, MAFbx, and USP28 mRNA were largely repressed after MG132 administration. β5 proteasome activity tended to increase in HU (+16.7 ± 6.1%, P = 0.086). Neither β1 and β2 proteasome activities nor ubiquitin-conjugated proteins were changed by HU. CONCLUSIONS: Our results indicate that in vivo administration of MG132 partially prevents muscle atrophy associated with disuse and highlight an unexpected regulation of MG132 proteasome inhibitor on ubiquitin-ligases.
Authors: Megan E Rosa-Caldwell; Seongkyun Lim; Wesley S Haynie; Lisa T Jansen; Lauren C Westervelt; Madeline G Amos; Tyrone A Washington; Nicholas P Greene Journal: J Appl Physiol (1985) Date: 2020-09-17
Authors: Pleuni E Hooijman; Albertus Beishuizen; Christian C Witt; Monique C de Waard; Armand R J Girbes; Angelique M E Spoelstra-de Man; Hans W M Niessen; Emmy Manders; Hieronymus W H van Hees; Charissa E van den Brom; Vera Silderhuis; Michael W Lawlor; Siegfried Labeit; Ger J M Stienen; Koen J Hartemink; Marinus A Paul; Leo M A Heunks; Coen A C Ottenheijm Journal: Am J Respir Crit Care Med Date: 2015-05-15 Impact factor: 21.405
Authors: Telma F Cunha; Aline V N Bacurau; Jose B N Moreira; Nathalie A Paixão; Juliane C Campos; Julio C B Ferreira; Marcelo L Leal; Carlos E Negrão; Anselmo S Moriscot; Ulrik Wisløff; Patricia C Brum Journal: PLoS One Date: 2012-08-03 Impact factor: 3.240